# HanBio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hanbio-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Total disclosed funding: $40M
- Latest round: Series A (Jan 28, 2022)
- Investors on record: 4

## About

Based in Shanghai, China, and established in 2021, HanBio Therapeutics is a biotechnology company that focuses on R&D new drugs for treating tumors. The company incubated by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd that focuses on R&D, production, and sales of antibody drugs, and listed on Shanghai Stock Exchange under the number of 688336. The company's CEO is Dr. Zhenping Zhu, who has more than 28 years of R&D experience in pharmaceutical company, including 3SBio Group, Kadmon Holdings, ImClone Systems. Also, Dr. Zhenping Zhu has applied for more than 150 patents, and has published more than 200 peer-reviewed scientific papers in international journals.

The company's product pipelines include three bispecific antibodies in the IND and pre-IND stages, and early-stage antibodies and other biologics products. Those new drugs take  the technology of therapeutic targets.

The company plans to perform preclinical research and clinical trials of multiple antibody and bispecific antibody products, and to introduce talents, and to establish company management system.

## Funding rounds

- Series A, Jan 28, 2022, $40M — OrbiMed Advisors, Yonghua Capital, Hankang Capital, Elikon Venture

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series A